Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 377
Views pdf: 184
DOI: https://doi.org/10.51298/vmj.v530i1B.6661
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Trần, V. H. Q., Nguyễn, T. T. H., & Phạm, H. T. (2023). RESULTS OF CHOPE REGIMEN IN PERIPHERAL T-CELL LYMPHOMA AT VIETNAM NATIONAL CANCER HOSPITAL. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6661

RESULTS OF CHOPE REGIMEN IN PERIPHERAL T-CELL LYMPHOMA AT VIETNAM NATIONAL CANCER HOSPITAL

Vũ Hoàng Quân Trần1,, Thị Thu Hường Nguyễn1, Huy Tần Phạm2
1 HMU
2 University Hospital of Medicine

Main Article Content

Abstract

Objective: To evaluate the treatment results of CHOPE regimen in peripheral T-cell lymphoma. Patients and Methods: Descriptive, case-cluster-study. Patients aged ≤ 65 years old with newly diagnosed peripheral T-cell lymphoma at Vietnam National Cancer Hosptial from May 2019 to June 2023 were enrolled to receive CHOPE every three weeks for at least three cycles. Results: The study was carried out on 35 patients. Median age was 39,5 ± 12,7; male:female ratio was 2,5:1. Palpable lymphadenopathy was the common presenting symptom (85,7%). A third of all patients had extralymph node disease (31,4%). The majority of patients (54,3%) had PTCL, NOS and 51,5% patients were in stage III or IV. Complete response rate after 3 cycles was 45,7%, after 6 cycles was 75%. The mean progression-free disease was 28,13 ± 3,44 months. The most common adverse effects were hematologic toxicities. Conclusion: CHOPE regimen was safe and high effective in peripheral T-cell lymphoma  

Article Details

Keywords

Non-Hodgkin lymphoma, Periopheral T-cell, CHOPE

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. May 2021;71(3):209-249.
2. Wang SS VJ. Epidemiology and Prognosis of T-Cell Lymphoma. Foss, F, editor T-cell Lymphomas Humana Press. 2013:25–39.
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. Jun 1 1997;89(11):3909-18.
4. Huang Y, Lin TY, Wu QL, et al. [Survival outcomes of T-cell non-Hodgkin's lymphoma: a report of 111 cases]. Ai Zheng. Apr 2005;24(4):470-4.
5. Liu X, Yang M, Wu M, et al. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. Cancer Chemotherapy and Pharmacology. 2019;83(3):443-449.
6. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. Nov 4 2010;116(18):3418-25.
7. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. Aug 1 2004;104(3):634-41.
8. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. Sep 1 2008;26(25):4124-30.
9. Jia B, Hu S, Yang J, et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology. Oct 2016;21(9):536-41.
10. Nguyễn Thị Thu Hường. Đánh giá kết quả điều trị phác đồ CHOPE trên bệnh nhân u lympho không Hogdkin tế bào T. Tạp chí Y học Việt Nam tập 497 tháng 12 số chuyên đề Ung thư năm 2020 BV1. 2020:302-308.